Log In | Register
Researchers are one bureaucratic hurdle away from gaining approval for the first clinical examination on the benefits of marijuana for veterans suffering from post-traumatic stress disorder (PTSD). The Multidisciplinary Association for Psychedelic Studies (MAPS), working under the auspices of the University of Arizona College of Medicine, are preparing a three-month study of combat veterans who served in Iraq and Afghanistan. The plan is on hold until the National Institute on Drug Abuse and Public Health Service (part of the Department of Health and Human Services) agrees to sell researchers the marijuana needed for research -- or until the marijuana can be legally imported. Social and political intrigue surrounding this research is far reaching, attracting opposing factions who must cede biases for the greater good and well-being of servicemen and servicewomen.
The University-controlled study Sisley advocates calls for a triple-blind and placebo-controlled environment. A meticulously prepared proposal recommends a sample base of 50 veterans, whose PTSD symptoms have not improved under current standard medical practices. All participants must agree to abstain from marijuana use for 30 days prior to participation. In two ensuing 60-day periods, the veterans are asked to either smoke or vaporize a maximum of 1.8 grams of marijuana a day (the equivalent of two marijuana cigarettes). The test group will be furnished a weekly supply of various strains of marijuana, with THC levels ranging from 0 percent to 12 percent. Sisley's study objectives are twofold. "With this research, we can actually figure out which symptoms it might help with, and what an optimal dosing strategy might look like." She is also mindful of public opinion regarding medical marijuana. "If we get a chance to do this, we're not taking liberties. This is a carefully controlled, rigorous scientific study. We're not sitting around trying to get these vets high."
